Pharmaceutical

Lilly sales fall, drugmaker to keep rep count low

Lilly sales fall, drugmaker to keep rep count low

Cymbalta and Evista patent losses drove down sales, but Lilly said it does not plan to replenish the sales force it thinned in anticipation of the decline.

Claims show BMS's Abilify remains strong

The antipsychotic's hold on the market has been steady, despite generics of drugs such as AstraZeneca's Seroquel.

App may diagnose glaucoma

Researchers say the iPad app could help assess vision loss.

Five things for pharma marketers to know: Thursday, October 23

Five things for pharma marketers to know: Thursday, October 23

FDA panel endorses Novartis psoriasis drug; court rules with Pfizer on cancer drug patent; drugmakers may look for indemnity against losses from Ebola vaccines.

Biogen's strong quarter eclipsed by patient death

Biogen's strong quarter eclipsed by patient death

Despite strong performance by its MS therapies, the drugmaker's robust third-quarter sales were overshadowed by the death of a patient taking Tecfidera.The patient had a rare brain infection.

GSK restructures, as respiratory disappoints

GSK restructures, as respiratory disappoints

GlaxoSmithKline's third-quarter sales fell 10% for the quarter, compared to last year, and new Ellipta products failed to cushion the 24% drop in US Advair sales.

NIH tests second Ebola vax in humans

Canada's National Microbiology Laboratory developed the vaccine, which has been licensed to NewLink Genetics Corp.

Actavis, Sanofi reportedly spar for Omega

Bloomberg reports that the race to merge with Omega also includes privately-held Boehringer Ingelheim and Perrigo.

Senate hearing may be on horizon for HCV drug prices

Sen. Bernard Sanders (I-VT) could hold a hearing after midterm elections to discuss the impact of costly new HCV treatments on the US Department of Veterans' Affairs.

Study hints at how brands should reach Millennials

Study hints at how brands should reach Millennials

The Post X-er, Post-Boomer generation considers traditional healthcare "sick care."

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.